Acacia Pharma Group PLC ACPH-BE:Euronext Brussels

*Data is delayed | EUR
Last | 03/02/21 CET
2.77UNCH (UNCH)
52 week range
1.61 - 3.54

...

Loading . . .

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close2.77
  • 52 Week High3.54
  • 52 Week High Date06/09/20
  • 52 Week Low1.61
  • 52 Week Low Date03/17/20
  • Market Cap224.95M
  • Shares Out67.86M
  • 10 Day Average Volume368,837.18
  • Dividend-
  • Dividend Yield-
  • Beta2.06
  • 1 Year % Change-7.21

RATIOS/PROFITABILITY

  • EPS (TTM)-0.37
  • P/E (TTM)-7.45
  • Fwd P/E (NTM)-
  • EBITDA (MRQ)-
  • ROE (MRQ)-
  • Revenue (MRQ)-
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest Acacia Pharma Group PLC News

There is no recent news for this security.

Latest ACPH-BE News From Our Partners

There is no recent news for this security.

QUOTE FINDER

Profile

MORE
Acacia Pharma Group PLC is a United Kingdom-based company specialized in the pharmaceutical industry. The pharmaceutical group focuses on the development and commercialization of new nausea and vomiting treatments for surgical and cancer patients. Its pipeline includes BAREMIS, an intravenous formulation of amisulpride, which is a selective dopamine antagonist that has completed phase 3 clinical development for the prophylaxis and treatment of Postoperative nausea and...
Michael Bolinder
Chief Executive Officer
Gary Gemignani
Chief Financial Officer
Address
The Officers Mess Business Centre
Royston Road
Cambridge
CB22 4QH
United Kingdom